The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
14 November, 2011